Q3FY17 Results : Suven Life Sciences

Bhagyashree Vivarekar / 01 Feb 2017

Q3FY17 Results : Suven Life Sciences

The company's PAT of Rs 24.2 crore represented a sequential QoQ decline of 8.68 per cent and a YoY increase of 42.35 per cent.

Suven Life Sciences Ltd. reported its standalone results for the quarter ended December 31, 2016 today. 

The company's sales for Q3FY17 largely flat at Rs 115.5 crore as compared to the last quarter buy recorded YoY increase of 2.39 per cent .

Its operating profit (EBIT) for the quarter was Rs. 32 crore, while its EBIT margin was 27.71 per cent.

The company's PAT of Rs 24.2 crore represented a sequential QoQ decline of 8.68 per cent and a YoY increase of 42.35 per cent.

Suven Life Sciences Ltd is an Indian company engaged in the business of designing, manufacturing and supplying of bulk actives, drug intermediates and fine chemicals. The company operates in three segments, viz. manufacturing (Intermediates under contract services products are developed and produced on an exclusive basis under contract manufacturing services), services [DDDSS] (consisting of collaborative research projects (CRP), clinical trials and testing and analysis services) and research & development.

If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.